Lifesci Capital Brokers Lower Earnings Estimates for AQST

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Investment analysts at Lifesci Capital decreased their Q2 2026 earnings estimates for Aquestive Therapeutics in a report issued on Friday, May 15th. Lifesci Capital analyst F. Brisebois now expects that the company will earn ($0.12) per share for the quarter, down from their prior estimate of ($0.11). The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.46) per share. Lifesci Capital also issued estimates for Aquestive Therapeutics’ Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.15) EPS and FY2026 earnings at ($0.48) EPS.

AQST has been the topic of several other reports. Oppenheimer initiated coverage on shares of Aquestive Therapeutics in a research note on Friday, April 24th. They issued an “outperform” rating and a $8.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Monday, April 20th. Wall Street Zen upgraded shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Lake Street Capital set a $6.00 price target on shares of Aquestive Therapeutics in a research note on Tuesday, February 3rd. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Aquestive Therapeutics presently has an average rating of “Buy” and an average price target of $8.80.

Aquestive Therapeutics Stock Performance

AQST stock opened at $4.14 on Tuesday. The company’s 50 day moving average price is $4.16 and its 200 day moving average price is $4.74. Aquestive Therapeutics has a fifty-two week low of $2.22 and a fifty-two week high of $7.55. The firm has a market capitalization of $519.36 million, a price-to-earnings ratio of -6.79 and a beta of 1.50.

Aquestive Therapeutics (NASDAQ:AQST) last released its earnings results on Wednesday, May 13th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.07. The firm had revenue of $14.45 million for the quarter, compared to analysts’ expectations of $10.90 million.

Institutional Investors Weigh In On Aquestive Therapeutics

Several large investors have recently modified their holdings of AQST. NewEdge Advisors LLC acquired a new stake in shares of Aquestive Therapeutics in the third quarter valued at approximately $28,000. BNP Paribas Financial Markets boosted its holdings in shares of Aquestive Therapeutics by 78.3% in the second quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock valued at $31,000 after acquiring an additional 4,134 shares during the period. Modern Wealth Management LLC acquired a new stake in shares of Aquestive Therapeutics in the second quarter valued at approximately $33,000. Elevation Point Wealth Partners LLC acquired a new stake in shares of Aquestive Therapeutics in the first quarter valued at approximately $42,000. Finally, ADAR1 Capital Management LLC boosted its holdings in shares of Aquestive Therapeutics by 103.9% in the first quarter. ADAR1 Capital Management LLC now owns 10,000 shares of the company’s stock valued at $42,000 after acquiring an additional 264,000 shares during the period. 32.45% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Aquestive Therapeutics news, insider Lori J. Braender sold 40,102 shares of the stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $4.17, for a total value of $167,225.34. Following the transaction, the insider directly owned 442,879 shares in the company, valued at $1,846,805.43. This represents a 8.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Daniel Barber sold 180,677 shares of the stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $4.17, for a total transaction of $753,423.09. Following the completion of the transaction, the chief executive officer owned 1,004,753 shares in the company, valued at $4,189,820.01. This represents a 15.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 403,947 shares of company stock valued at $1,685,450 over the last three months. 6.81% of the stock is currently owned by insiders.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.